7803-58-9

Basic information

• Product Name: Sulfamide
• Synonyms: Sulfamamide;SulfaMide, 98+% 5GR;SulfaMid;Sulphamide 99%;Sulfamide purum, >=99.0% (N);[S(NH2)2O2];diamidodioxidosulfur;Imidosulfamic acid (VAN)
• CAS NO: 7803-58-9
• Molecular Formula: H₄N₂O₂S
• Molecular Weight: 96.11
• EINECS: 232-262-9
• Product Categories: Pharmaceutical intermediates;Starting Raw Materials & Intermediates;Inorganics;Chemical Amines;Famotidine;Amines;Inhibitors;Sulfur & Selenium Compounds;Electronic Chemicals;Micro/Nanoelectronics;Others
• Mol File: 7803-58-9.mol

Chemical Properties

• Melting Point: 90-92 °C(lit.)
• Appearance: White to practically white , free from visible impurities/Crystalline Powder, Free From Visible Impurities
• Density: 1.611 g/mL at 25 °C(lit.)
• Refractive Index: 1.548
• Storage Temp.: Refrigerator
• Solubility: water: soluble50mg/mL, clear, colorless to faintly yellow
• PKA: 10.87±0.60(Predicted)
• Water Solubility: soluble
• Sensitive: Moisture Sensitive
• Merck: 14,8922
• CAS DataBase Reference: Sulfamide(CAS DataBase Reference)
• NIST Chemistry Reference: Sulfamide(7803-58-9)
• EPA Substance Registry System: Sulfamide(7803-58-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37/39
• WGK Germany: 3
• F: 9
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 7803-58-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Sulfamide is used as a pharmaceutical intermediate for the development of various drugs due to its carbonic anhydrase inhibitory properties.
Used in Cancer Treatment:
Sulfamide is used as a carbonic anhydrase inhibitor for the treatment of cancer, helping to regulate the activity of the enzyme involved in various physiological processes.
Used in Organic Chemistry:
Sulfamide and its derivatives are used to prepare fused thiadiazine systems. Reaction with 2-aminoacetophenones affords IH-2,1,3-benzothia-diazin-2,2-dioxides. The corresponding 3,4-dihydro derivatives can be obtained from 2-aminobenzylamines with either sulfuryl chloride or sulfamide. These compounds can also be synthesized from N-aryl-N'-alkylsulfamides and s-trioxane in a reaction involving cyclization by intramolecular sulfamido-methylation.
Used as a Dibasic Acid:
Similar to urea in many of its reactions, sulfamide is more acidic and can act as a dibasic acid, finding applications in various chemical processes and formulations.

Purification Methods

Crystallise sulfamide from absolute EtOH. It decomposes at 250o. [Schenk in Handbook of Preparative Inorganic Chemistry (Ed. Brauer) Academic Press Vol I pp 482-483 1963.]

InChI:InChI=1/H4N2O2S/c1-5(2,3)4/h(H4,1,2,3,4)

Upstream product

• 5329-14-6 aminosulfonic acid 
• 57-13-6 urea 
• 7446-11-9 sulfur trioxide 
• 7664-41-7 ammonia 
• 7803-49-8 hydroxylamine 
• 7757-83-7 sodium sulfite 
• 7791-27-7 pyrosulfuryl chloride 
• 4223-09-0 sulfonyl diisocyanate 
• 7732-18-5 water 
• 3481-04-7 phthalimide sulfonic acid chloride 
• 7791-25-5 sulfuryl dichloride 
• 1074-82-4 potassium phtalimide 
• 80937-33-3 oxygen 
• 7704-34-9 sulfur 

Downstream Products

• 144432-67-7 3,3-dimethyl-1,2,5-thiadiazolidine-1,1-dioxide 
• 85694-52-6 2-isopropyl-1,2,5-thiadiazolidine-1,1-dioxide 
• 144432-72-4 2-benzyl-1,2,5-thiadiazolidine 1,1-dioxide 
• 933984-13-5 C₂₃H₃₀N₄O₄S 
• 79099-04-0 3,4-dihydro-2,2-dioxido-3-[1-(phenylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazine 
• 79099-05-1 1-benzyl-4-(3,4-dihydro-2,2-dioxo-1H-2,1,3-benzothiadiazin-1-yl)piperidine.HCl 
• 7647-01-0 hydrogenchloride 
• 14259-65-5 bis-{trichloro-phosphazo}-sulfone 
• 7664-93-9 sulfuric acid 
• 7664-41-7 ammonia 
• 5329-14-6 aminosulfonic acid 
• 31218-37-8 NH₂SO₂NHSO₂Cl 
• 51803-20-4 benzylidensulfurylamide 
• 125984-21-6 Pt{(HN)2SO₂}(PPh₂Me)2 

Relevant articles and documents

Compounds useful for treating AIDS

The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS. The present invention further relates to compounds of formula (I) wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a -CN group, a -COORa group, a -NO2 group, a -NRaRb group, a -NRa-SO2-NRaRb group, a -NRa-SO2-Ra group, a -NRa-C(=O)-Ra group, a -NRa-C(=O)-NRaRb group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group, a -O-P(=O)-(ORc)(ORd) group, a -O-CH2-COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.

METHOD FOR PRODUCING IMIDIC ACID COMPOUND

Disclosed is a method for producing "a salt or a complex comprising imidic acid and an organic base", characterized by reacting halogenated sulfuryl or halogenated phosphoryl with ammonia in the presence of an organic base. According to this method, a target imidic acid compound can be produced in a high yield while significantly suppressing the production of by-products. Further, by reacting the obtained imidic acid compound with an alkali metal hydroxide or an alkaline earth metal hydroxide, an imidic acid metal salt can be easily derived.

2,3-oxidosqualene-lanosterol cyclase inhibitors

The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the alphavbeta3 integrin.

BENZIMIDAZOLE DERIVATIVES

The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: wherein R1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group: R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; R3 represents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.

Synthesis of 1,3,5-trisubstituted pyrazoles

A novel process for making 1,3,5-trisubstituted pyrazoles of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.

METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS

Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-γ in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-γ inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-γ in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

Sulfonamide substituted aspartic acid interleukin-1 beta converting enzyme inhibitors

PCT No. PCT/US97/18406 Sec. 371 Date Apr. 9, 1999 Sec. 102(e) Date Apr. 9, 1999 PCT Filed Oct. 9, 1997 PCT Pub. No. WO98/16504 PCT Pub. Date Apr. 23, 1998The present invention relates to compounds that are inhibitors of interleukin-1 beta converting enzyme that have the Formula I, II, or III. This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 beta converting enzyme.

Meta-substituted phenylene sulphonamide derivatives

The present invention relates to a class of compounds represented by the Formula I STR1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αv β3 integrin.

Cyclised analogues of fatty acid metabolites

A compound selected from those of formula (I): STR1 wherein A, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the description. This compound or its physiologically tolerable salts may be used therapeutically as platelet anti-aggregation agent.